Frank Stokes - Aug 7, 2024 Form 4 Insider Report for CASTLE BIOSCIENCES INC (CSTL)

Role
Chief Financial Officer
Signature
/s/ Frank Stokes, Attorney-in-fact
Stock symbol
CSTL
Transactions as of
Aug 7, 2024
Transactions value $
-$256,997
Form type
4
Date filed
8/13/2024, 06:13 PM
Previous filing
Jun 12, 2024
Next filing
Aug 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CSTL Common Stock Sale -$116K -4.6K -11.27% $25.20 36.2K Aug 7, 2024 Direct F1, F2, F3
transaction CSTL Common Stock Sale -$141K -5.4K -14.91% $26.13 30.8K Aug 7, 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024.
F2 This transaction was executed in multiple trades at prices ranging from $24.840 to $25.535, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes 1,272 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan.
F4 This transaction was executed in multiple trades at prices ranging from $25.845 to $26.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.